Published

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Clinical Medicine
Date: 2026-08-12
Source: Crossref
DOI: 10.3390/jcm15166228
PubMed: Unavailable

Authors

Anghel Teodora Cojocaru Adriana Hogea Lavinia Costea Iuliana Marinca Amalia Dumache Raluca Nussbaum Laura Trăilă Iuliana-Anamaria

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction Mechanism of Action Randomized Controlled Trial Systematic Review Review Article Cancer Patients Treatment-Resistant Depression Veterans Safety Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1124/pr.115.011478 10.1016/s0893-133x(96)00246-1 10.3389/fpsyt.2025.1588902 10.1177/00048674241240597 10.3389/fpsyt.2026.1777387 10.1001/jamapsychiatry.2022.4101 10.4088/jcp.24m15449 10.1016/j.jad.2024.09.133 10.1177/02698811251362390 10.1556/2054.2023.00297 10.1002/hlca.19590420518 10.3390/pharmaceutics17040411

Indexed papers citing this DOI

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)2026-08-12

Related papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23